Tired of pills? Harvard expert reveals natural diet tricks to crush bad cholesterol
Harvard Medical School
has brought the conversation back to basics—your kitchen. If you're battling high cholesterol levels, especially the LDL kind often dubbed 'bad' cholesterol, you may want to check your plate before your prescription. According to Harvard Health Publishing, small dietary changes can significantly lower LDL levels and improve heart health.
The Fiber Fix: Soluble Secrets to Success
As reported by The Mirror, at the heart of this natural remedy is something we often overlook- soluble fiber. Found in whole grains, oats, fruits, vegetables, and legumes, soluble fiber acts like a sponge in the digestive tract. It binds with cholesterol and flushes it out of the body before it enters the bloodstream. Kathy McManus, Director of Nutrition at Brigham and Women's Hospital, emphasized in her conversation with Harvard Health Publishing that what you eat is as crucial as your genes when it comes to managing cholesterol.
Whole grains like traditional oatmeal (not the instant kind), brown rice, and barley are strongly recommended. 'Instead of refined flour and white rice, try whole-wheat flour and brown or wild rice,' the experts advised. These foods not only support cholesterol control but also offer sustained energy and improved digestion.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Tiger meeting her former zookeeper after 5 years. See what happens next!
Story To Hear
Undo
iStock
Whole grains like traditional oatmeal (not the instant kind), brown rice, and barley are strongly recommended to beat cholestrol. (Image: iStock)
Don't Swap Fat for Sugar
One common dietary blunder, McManus warns, is replacing fat with sugar in the quest for 'healthy' eating. This approach can backfire, potentially elevating triglycerides and undermining cardiovascular health. The message is clear: steer away from sugary substitutes and opt for naturally nutrient-dense options like lentils, chickpeas, and tofu.
Add Color and Oil the Right Way
UHSussex, in alignment with Harvard's findings, also noted that a diet rich in colorful fruits and vegetables is essential. Not only do these foods offer a broad spectrum of antioxidants, but they also contain plant-based proteins that are low in fat and high in fiber. When it comes to cooking oils, plant-based sources like olive, walnut, and flaxseed oil, along with omega-3-rich fish such as salmon, can play a pivotal role in managing LDL cholesterol.
You Might Also Like:
Harvard doctor's urgent advice: Throw these 3 items from your house immediately
While lifestyle changes offer remarkable benefits, those with familial hypercholesterolemia—an inherited condition—may still require medication. However, even in these cases, diet remains a vital part of a comprehensive health strategy. 'Check with your doctor, but know that your fork can often be your first line of defense,' the Harvard team suggested.
The Bigger Picture
With heart disease and circulatory conditions responsible for nearly one in three adult deaths annually in the United States, the findings underscore the importance of preventative healthcare. As these experts emphasize, managing cholesterol isn't just about cutting things out—it's about thoughtfully adding in the right ingredients.
Whether you're dealing with a recent diagnosis or simply aiming for a healthier lifestyle, it might be time to rediscover your spice rack and grain drawer. Sometimes, the answer to a healthier heart starts not in a pharmacy, but in your pantry.
You Might Also Like:
Harvard doctor warns: Get rid of these 3 common bedroom items before they secretly ruin your health
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
16 minutes ago
- Time of India
Bihar leads nation in free medicine supply in hosps
1 2 Patna: Bihar has secured the top position in the country for the eleventh consecutive month in the supply and distribution of free medicines in govt hospitals, according to the central govt's Drugs and Vaccine Distribution Management System (DVDMS) portal, health minister Mangal Pandey said on Thursday. He attributed the achievement to the state govt's commitment to improving public health and delivering quality healthcare services. "With the aim to make health services accessible and timely to the people, new hospitals are being constructed and health workers continuously appointed in the state under the leadership of PM Narendra Modi and CM Nitish Kumar," Pandey said. Citing data from the DVDMS portal, the minister said Bihar led the country with 82.13 points, followed by Rajasthan with 78.61 and Punjab with 73.28. He added that Bihar's policy of free medicine distribution was approved by the cabinet on July 1, 2006. "In 2006, only 47 types of medicines were available. At present, this number has increased to 611. In addition, 20 other types of medicines and 132 types of medical devices and consumables are also being provided for free. Now every patient visiting govt hospitals in the state is receiving medicines as per requirement without any charge," Pandey said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like These Are The Most Beautiful Women In The World Undo Highlighting improvements in maternal and child health indicators, he said, "The maternal mortality rate was 365 in 2005. It has now come down to 91. The infant mortality rate has decreased to 27, which is equal to the national average. The mortality rate of children under five has dropped to 29, which is better than the national average. The neonatal mortality rate (0-28 days) now stands at 19, again on par with the national average," he said. According to the minister, the state has promoted institutional deliveries, leading to a reduction in home births. Vaccination coverage in Bihar has also reached 95% based on Health Management Information System (HMIS) data. "Under the Ayushman Bharat scheme, Bihar has achieved the target of generating four crore Ayushman cards and currently holds the third position in the country in this regard," Pandey added. Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and s ilver prices in your area.
Time of India
20 minutes ago
- Time of India
Ditch your glasses - breakthrough eye drops approved by FDA to fix your near vision instantly
In a major medical breakthrough, the U.S. Food and Drug Administration has approved Vizz, a once daily eye drop that helps improve near vision without the need for reading glasses. Created by Lenz Therapeutics , Vizz is the first eye drop to use aceclidine, a compound that temporarily reduces pupil size to sharpen close up focus. The eye drop works by creating a mild "pinhole effect" that extends the eye's depth of focus, improving the ability to see things up close. Vizz is fast acting, with noticeable improvement in vision within 30 minutes, and the benefits can last for up to 10 hours with just one drop a day. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Strong clinical results with minimal side effects Vizz was approved after being tested in three major Phase 3 trials CLARITY 1, 2, and 3. These studies involved hundreds of participants over several weeks and months. Results showed that a majority of users gained a three-line improvement in near vision on a standard eye chart, a strong indicator of effectiveness. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Become Fluent in Any Language Talkpal AI Undo Even more reassuring, the safety profile was excellent. No serious side effects were reported. A small number of users experienced mild symptoms like eye irritation, headache, or dim vision, but these effects were temporary and resolved without treatment. Importantly, Vizz did not negatively affect distance vision, making it practical for everyday use. A modern alternative for aging eyes Vizz could be a game changer for the estimated 128 million Americans living with presbyopia . Rather than relying on glasses or surgical options, patients now have access to a non-invasive, convenient treatment they can use daily. The drops are expected to be available in the U.S. by late 2025, starting with sample distributions in doctors' offices. Live Events This approval marks a turning point in eye care innovation. With its fast results, strong safety data, and ease of use, Vizz offers new hope to people who want to regain near vision clarity and reduce their dependence on corrective lenses. FAQs: Q1. What is presbyopia? A1. Presbyopia is a common condition where the eye's lens loses flexibility, making it hard to focus on close-up objects. It typically starts after the age of 40. Q2. Why does near vision get worse with age? A2. As we age, the lens inside the eye becomes less flexible. This makes it harder for the eye to adjust and focus on close objects.
Time of India
2 hours ago
- Time of India
Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could lose
Eli Lilly's weight loss pill doesn't appear to work as well as Wall Street had hoped. The drugmaker said Thursday the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial. The result falls on the lower end of Wall Street's expectations. Shares of the company fell around 13% on Thursday, according to CNBC. Meanwhile, shares of rival Novo Nordisk, which is also working to bring an obesity pill to the market, jumped more than 7% on Thursday. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Eli Lilly, which makes the injectable drugs Zepbound to treat obesity and Mounjaro and Trulicity to treat diabetes, is among several companies chasing an effective pill form of GLP-1s. The only such pill available so far comes with strict diet restrictions and is approved to treat diabetes. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Web Search search Search Now Undo Lilly says that no food or water restrictions are needed with the experimental oral medication, orforglipron, and it can be taken any time of day. ALSO READ: Firefly Aerospace ignites Wall Street as it raises $868 million in biggest space IPO. All about SpaceX rival Live Events Eli Lily on daily GLP-1 pills Eli Lilly announced that its new orforglipron pill led to an average weight loss of up to 27.3 pounds, based on results from the first of two Phase 3 trials involving over 3,100 overweight or obese adults. "With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments," Kenneth Custer, an executive vice president and president of Lilly Cardiometabolic Health, said in a statement. "With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need." ALSO READ: VA terminates major union contracts and it will impact over 400,000 federal workers. What's at stake for you? Investors had high hopes that Lilly's pill, orforglipron, would match the effectiveness of Novo Nordisk's blockbuster weight-loss injection, Wegovy. In key trials, Wegovy helped users lose around 14% to 15% of their body weight — slightly below the weight loss seen with Lilly's competing shot, Zepbound. 'There was hope that this would be a wonder drug,' BMO analyst Evan Seigerman said of Lilly's pill. 'What this shows to me is that it's still a good drug, but it's bound by the limitations of being a GLP-1.' Eli Lilly said that all adults participating in its Phase 3 trials experienced weight loss while taking orforglipron. Participants on the highest dose—36 mg—lost an average of 27 pounds over 72 weeks, equating to about 12% of their body weight. While this result is significant, it falls slightly short of the weight loss typically seen with some injectable treatments with the drugmaker noticing that about 10% of participants on the highest dose chose to discontinue the pill. ALSO READ: $1,702 stimulus check in August: Last chance to apply for PDF closes soon. Check key dates, eligibility, tax implication Beyond weight loss, trial participants saw improvements in cardiovascular markers, including reductions in systolic blood pressure, non-HDL cholesterol, and triglycerides. Negative side effects were similar in frequency and nature to those observed with injectable GLP-1 medications. The most commonly reported side effects were mild to moderate gastrointestinal issues such as nausea, constipation, indigestion, diarrhea, and vomiting. Eli Lilly is also evaluating orforglipron's effectiveness in adults with Type 2 diabetes. In April, the company shared that the pill may help lower hemoglobin A1C levels—a key indicator of average blood sugar over two to three months—while also supporting weight loss. Eli Lilly aims to seek global regulatory approval for its daily oral orforglipron pill by the end of 2025, positioning itself alongside rival Novo Nordisk, which is pursuing approval for an oral form of its Wegovy (semaglutide) treatment. However, federal health regulators are expected to require more comprehensive data on the drug's safety, tolerability, and effectiveness before moving forward with any potential approval.
